Genmab A/S (NASDAQ:GMAB) Stock Acquired Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Genmab A/S NASDAQ: GMAB. In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genmab A/S stock on January 16th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 1/31/2025.
• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Mastercard NYSE: MA on 1/31/2025.
• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of 3M NYSE: MMM on 1/30/2025.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded up $0.38 on Friday, hitting $21.30. The company had a trading volume of 2,417,574 shares, compared to its average volume of 1,682,134. The firm has a market capitalization of $14.10 billion, a P/E ratio of 20.68, a P/E/G ratio of 0.54 and a beta of 0.96. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The stock has a 50-day moving average of $20.65 and a 200-day moving average of $23.15.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Equities analysts predict that Genmab A/S will post 1.25 EPS for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC increased its holdings in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.17.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.